Wedbush started coverage on shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) in a research note published on Thursday. The brokerage issued an outperform rating and a $13.00 price target on the biopharmaceutical company’s stock.
A number of other research firms have also issued reports on ACHN. Robert W. Baird reiterated an outperform rating and set a $10.00 target price on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. Leerink Swann reiterated a hold rating on shares of Achillion Pharmaceuticals in a report on Sunday, June 12th. Jefferies Group reiterated a hold rating on shares of Achillion Pharmaceuticals in a report on Tuesday, August 9th. Chardan Capital initiated coverage on shares of Achillion Pharmaceuticals in a report on Thursday, July 14th. They issued a sell rating and a $4.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, August 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $10.70.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 8.34 on Thursday. Achillion Pharmaceuticals has a one year low of $5.57 and a one year high of $10.95. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of 170.20 and a beta of 2.21. The company’s 50-day moving average is $8.46 and its 200 day moving average is $8.43.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. During the same quarter last year, the business earned ($0.25) EPS. Equities analysts expect that Achillion Pharmaceuticals will post ($0.61) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of ACHN. Schonfeld Strategic Advisors LLC bought a new position in Achillion Pharmaceuticals during the first quarter worth approximately $101,000. Fox Run Management L.L.C. bought a new position in Achillion Pharmaceuticals during the second quarter worth approximately $105,000. Investment Centers of America Inc. increased its position in Achillion Pharmaceuticals by 27.7% in the second quarter. Investment Centers of America Inc. now owns 13,733 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 2,975 shares during the period. Princeton Alpha Management LP bought a new position in Achillion Pharmaceuticals during the second quarter worth approximately $109,000. Finally, Teacher Retirement System of Texas increased its position in Achillion Pharmaceuticals by 13.0% in the second quarter. Teacher Retirement System of Texas now owns 15,173 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 1,749 shares during the period. 79.43% of the stock is currently owned by hedge funds and other institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.